Perampanel is a first-in-class, noncompetitive, α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor antagonist recently approved for the adjunctive treatment of partial seizures in patients 12 years of age and older when other antiepileptic medications have failed.
Indications
- Approved Use:
- EU and US: For patients with epilepsy aged 12 years and older.
- Adjunctive treatment for:
- Primary generalized tonic-clonic seizures (GTCS)
- Partial-onset seizures (POS), with or without secondary generalization.
Mechanism of Action
- European Commission: July 2012
- FDA: October 2012